Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY E RITTER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1235115189
CMS profile
55378
Location
SOUTHLAKE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$140,768.50

210 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY E RITTER

NPI 1235115189 · CMS profile ID 55378

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SOUTHLAKE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235115189?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY E RITTER, NPI 1235115189, CMS profile ID 55378. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235115189?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). TIMOTHY E RITTER, NPI 1235115189, CMS profile ID 55378. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235115189?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
TIMOTHY E RITTER, NPI 1235115189, CMS profile ID 55378, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1235115189?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

210 matching records · $140,768.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 210 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 210.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $110.0109/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456725 CMS
ABBVIE INC. $27.2109/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456723 CMS
Organon LLC $14.7109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946412391 CMS
ABBVIE INC. $2,875.0009/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456721 CMS
E.R. Squibb & Sons, L.L.C. $2,420.0009/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932603485 CMS
Celgene Corporation $22.4609/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932603489 CMS
Janssen Scientific Affairs, LLC $3,850.0009/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274773 CMS
Janssen Scientific Affairs, LLC $20.6309/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274797 CMS
Lilly USA, LLC $35.9209/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918287225 CMS
ABBVIE INC. $22.3709/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456719 CMS
ABBVIE INC. $54.4609/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456717 CMS
Merck Sharp & Dohme LLC $18.0809/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944213819 CMS
Janssen Scientific Affairs, LLC $397.1109/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274777 CMS
Janssen Scientific Affairs, LLC $330.2509/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274785 CMS
Janssen Scientific Affairs, LLC $22.4709/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274791 CMS
Echosens North America, Inc. $89.2309/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 877936449 CMS
Janssen Scientific Affairs, LLC $107.3909/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274823 CMS
ABBVIE INC. $120.3309/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456715 CMS
Janssen Biotech, Inc. $20.0509/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886665347 CMS
PFIZER INC. $19.6909/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949335187 CMS
ABBVIE INC. $394.6009/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456711 CMS
ABBVIE INC. $17.8409/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456713 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959391167 CMS
Janssen Scientific Affairs, LLC $3,850.0009/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274765 CMS
Janssen Biotech, Inc. $28.7308/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886665329 CMS
Janssen Scientific Affairs, LLC $2,475.0008/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274757 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.7308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955797853 CMS
Janssen Scientific Affairs, LLC $3,850.0008/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274743 CMS
Janssen Scientific Affairs, LLC $2,475.0008/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274751 CMS
ABBVIE INC. $2,875.0008/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456707 CMS
ABBVIE INC. $4,025.0008/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456709 CMS
Celgene Corporation $24.8008/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932603477 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $31.2008/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959593049 CMS
ABBVIE INC. $4,025.0008/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456703 CMS
ABBVIE INC. $28.5508/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456705 CMS
Janssen Scientific Affairs, LLC $27.9308/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274811 CMS
ABBVIE INC. $1,476.0008/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456695 CMS
ABBVIE INC. $344.2108/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456697 CMS
ABBVIE INC. $20.5108/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456699 CMS
ABBVIE INC. $262.2008/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456701 CMS
ABBVIE INC. $1,036.5008/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456687 CMS
ABBVIE INC. $92.4008/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456689 CMS
ABBVIE INC. $18.4908/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456691 CMS
ABBVIE INC. $149.1308/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456693 CMS
Braintree Laboratories, Inc. $50.1808/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898420425 CMS
ABBVIE INC. $27.1307/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456681 CMS
ABBVIE INC. $2,300.0007/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456683 CMS
ABBVIE INC. $2,300.0007/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456685 CMS
Ferring Pharmaceuticals Inc. $19.1207/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875360251 CMS
ABBVIE INC. $28.6507/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891456679 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $129,413.70 242
PY2020 $54,200.18 77
PY2021 $96,984.16 151
PY2022 $140,768.50 210
PY2023 $157,312.80 209
PY2024 $260,457.87 300
PY2025 $121,998.49 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,186.55 14
PY2025 Principal investigator $922,579.64 139
PY2024 Recipient $940.00 1
PY2024 Principal investigator $762,225.54 150
PY2023 Recipient $4,800.00 4
PY2023 Principal investigator $1,033,827.79 127
PY2022 Recipient $3,170.00 3
PY2022 Principal investigator $586,221.64 118
PY2021 Recipient $18,225.00 1
PY2021 Principal investigator $718,093.08 128
PY2020 Recipient $5,234.34 4
PY2020 Principal investigator $1,128,125.30 201
PY2019 Recipient $7,150.29 9
PY2019 Principal investigator $1,598,344.16 234

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

153 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,904.88 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404030
Principal investigator 1 Janssen Research & Development, LLC $12,875.06 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404037
Principal investigator 1 Janssen Research & Development, LLC $920.00 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404046
Principal investigator 1 Janssen Research & Development, LLC $15,962.35 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404059
Principal investigator 1 Janssen Research & Development, LLC $37,253.19 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404076
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404086
Principal investigator 1 Janssen Research & Development, LLC $10,763.20 12/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404103
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187892972
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 12/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223289844
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 12/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223289846
Recipient PFIZER INC. $780.00 12/16/2025 Covered Recipient Physician TOFACITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727047
Principal investigator 1 ABBVIE INC. $6,233.16 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANT
A Study to Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn Disease No dispute reported 06/30/2026 1202530360
Principal investigator 1 ABBVIE INC. $941.00 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANT
A Study to Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn Disease No dispute reported 06/30/2026 1202530362
Principal investigator 1 ABBVIE INC. $152.00 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANT
A Study to Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn Disease No dispute reported 06/30/2026 1202530364
Principal investigator 1 ABBVIE INC. $4,476.10 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202528122
Principal investigator 1 F. Hoffmann-La Roche AG $10,353.00 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663006
Principal investigator 1 F. Hoffmann-La Roche AG $5,236.00 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,975.84 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184269611
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,851.10 11/26/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Southlake
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235993307
Principal investigator 1 Genentech, Inc. $2,618.00 11/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57,878.04 11/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184264393
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,832.00 11/21/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223288685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,771.62 11/20/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184263391
Principal investigator 1 PFIZER INC. $655.00 11/17/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228723464
Principal investigator 1 PFIZER INC. $1,824.00 11/17/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228739619
Principal investigator 1 PFIZER INC. $1,608.00 11/17/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228747497
Principal investigator 1 Genentech, Inc. $2,457.00 11/14/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663479
Principal investigator 1 Genentech, Inc. $13,615.00 11/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663466
Principal investigator 1 Genentech, Inc. $5,457.00 10/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,269.48 10/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184253909
Principal investigator 1 Genentech, Inc. $2,821.00 10/16/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663399
Principal investigator 1 PFIZER INC. $3,167.00 10/09/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228747786
Principal investigator 1 Genentech, Inc. $6,346.00 10/03/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663374
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,832.00 10/03/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223286377
Principal investigator 1 ABBVIE INC. $530.95 10/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202513145
Principal investigator 1 Janssen Research & Development, LLC $994.50 10/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404024
Principal investigator 1 Janssen Research & Development, LLC $7,707.35 10/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404052
Recipient PFIZER INC. $780.00 10/02/2025 Covered Recipient Physician TOFACITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727045
Principal investigator 1 Eli Lilly and Company $60,430.00 09/29/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 No dispute reported 06/30/2026 1187890860
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,899.50 09/25/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044700
Principal investigator 1 F. Hoffmann-La Roche AG $22,012.00 09/18/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,185.00 09/18/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184240828
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285383
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285385
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285419
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285425
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285446
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285450
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285452
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 09/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223285456
Principal investigator 1 F. Hoffmann-La Roche AG $20,706.00 09/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662937
Principal investigator 1 F. Hoffmann-La Roche AG $550.00 09/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662957
Principal investigator 1 F. Hoffmann-La Roche AG $550.00 09/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,808.44 09/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184236854
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,661.65 09/09/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,538.96 09/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184235365
Principal investigator 1 ABBVIE INC. $11,693.00 08/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202506515
Principal investigator 1 ABBVIE INC. $11,039.00 08/26/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202505959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,426.59 08/26/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184230543
Principal investigator 1 F. Hoffmann-La Roche AG $1,305.00 08/21/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662913
Principal investigator 1 F. Hoffmann-La Roche AG $21,151.00 08/14/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,185.00 08/14/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184228541
Principal investigator 1 Genentech, Inc. $9,344.00 08/13/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663325
Principal investigator 1 PFIZER INC. $3,167.00 08/08/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228742223
Principal investigator 1 PFIZER INC. $655.00 08/08/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228742451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,223.18 08/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184226453
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 07/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,808.44 07/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184223042
Principal investigator 1 Celgene Corporation $3,381.75 07/29/2025 Non-covered Recipient Entity
GI Alliance Department Of Clinical Research And Education
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222307113
Recipient PFIZER INC. $3,200.00 07/24/2025 Covered Recipient Physician TOFACITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726692
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 07/22/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,611.59 07/22/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184217987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,611.59 07/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184217360
Principal investigator 1 PFIZER INC. $655.00 07/11/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228743068
Principal investigator 1 F. Hoffmann-La Roche AG $1,600.00 07/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662965
Principal investigator 1 F. Hoffmann-La Roche AG $7,050.00 07/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211662971
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,833.10 07/10/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,892.72 07/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184213125
Principal investigator 1 ABBVIE INC. $6,739.20 07/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202496201
Principal investigator 1 Genentech, Inc. $3,161.00 06/19/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663231
Principal investigator 1 ABBVIE INC. $4,249.30 06/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202491257
Principal investigator 1 PFIZER INC. $1,435.00 06/09/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228792234
Principal investigator 1 Genentech, Inc. $16,500.00 05/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663121
Principal investigator 1 Genentech, Inc. $1,540.00 05/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663159
Principal investigator 1 Genentech, Inc. $3,400.00 05/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663206
Principal investigator 1 Genentech, Inc. $10,697.00 05/27/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663218
Principal investigator 1 Genentech, Inc. $2,512.00 05/23/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663268
Principal investigator 1 Janssen Research & Development, LLC $4,972.50 05/16/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404070
Principal investigator 1 Janssen Research & Development, LLC $2,983.55 05/16/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404081
Principal investigator 1 Genentech, Inc. $7,536.00 05/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663093
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,154.70 05/13/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044694
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 05/09/2025 Non-covered Recipient Entity
GI Alliance-Mansfield Endoscopy Center
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220732614
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 05/09/2025 Non-covered Recipient Entity
GI Alliance-Mansfield Endoscopy Center
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220732616
Principal investigator 1 Genentech, Inc. $6,280.00 05/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663284
Principal investigator 1 ABBVIE INC. $79.65 05/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202481867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,729.00 05/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223278924
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,450.65 04/29/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244044668
Principal investigator 1 PFIZER INC. $655.00 04/11/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228789889
Principal investigator 1 PFIZER INC. $1,435.00 04/11/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228791647
Principal investigator 1 Janssen Research & Development, LLC $2,983.44 04/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404092
Principal investigator 1 Janssen Research & Development, LLC $5,509.03 04/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404098
Principal investigator 1 Eli Lilly and Company $3,000.00 04/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187890858
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,910.75 04/01/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044690
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,100.00 04/01/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044692
Principal investigator 1 Eli Lilly and Company $70.25 03/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 No dispute reported 06/30/2026 1187892104
Principal investigator 1 Genentech, Inc. $25,120.00 03/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663060
Principal investigator 1 Janssen Research & Development, LLC $1,452.00 03/27/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404042
Principal investigator 1 Janssen Research & Development, LLC $3,480.82 03/27/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404065
Principal investigator 1 PFIZER INC. $2,601.40 03/19/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228777649
Principal investigator 1 Janssen Research & Development, LLC $6,793.93 03/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404109
Recipient SANOFI US SERVICES INC. $141.00 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129506
Recipient SANOFI US SERVICES INC. $794.93 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129512
Recipient SANOFI US SERVICES INC. $630.54 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129516
Recipient SANOFI US SERVICES INC. $75.00 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129537
Recipient SANOFI US SERVICES INC. $85.00 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129541
Recipient SANOFI US SERVICES INC. $74.49 03/14/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129546
Recipient SANOFI US SERVICES INC. $75.00 03/13/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129524
Recipient SANOFI US SERVICES INC. $85.00 03/13/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129527
Recipient SANOFI US SERVICES INC. $181.80 03/13/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129531
Recipient SANOFI US SERVICES INC. $101.99 03/13/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129534
Recipient SANOFI US SERVICES INC. $181.80 03/12/2025 Covered Recipient Physician A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease. No dispute reported 06/30/2026 1226129520
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 03/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 03/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276217
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
GI Alliance-Mansfield Endoscopy Center
Proof of Clinical Principal in Crohn's Disease No dispute reported 06/30/2026 1220997290
Principal investigator 1 Genentech, Inc. $1,256.00 03/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663030
Principal investigator 1 ABBVIE INC. $145.80 03/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202457269
Principal investigator 1 PFIZER INC. $1,824.00 03/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228777154
Principal investigator 1 PFIZER INC. $8,500.00 02/20/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC No dispute reported 06/30/2026 1228720569
Principal investigator 1 PFIZER INC. $6,494.00 02/17/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228776781
Principal investigator 1 ABBVIE INC. $1,321.65 02/05/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202445397
Principal investigator 1 Janssen Research & Development, LLC $38,222.74 02/03/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Sustained Humoral and Cell Mediated Immunogenicity of COVID19 Vaccines in Patients with Inflammatory Bowel Disease No dispute reported 06/30/2026 1175404018
Principal investigator 1 PFIZER INC. $655.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775051
Principal investigator 1 PFIZER INC. $655.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228776342
Principal investigator 1 PFIZER INC. $3,167.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228776644
Principal investigator 1 PFIZER INC. $655.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228776676
Principal investigator 1 PFIZER INC. $3,167.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228777599
Principal investigator 1 PFIZER INC. $1,435.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228784744
Principal investigator 1 PFIZER INC. $655.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228786060
Principal investigator 1 ABBVIE INC. $18,300.00 01/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202439879
Principal investigator 1 Celgene Corporation $51,849.10 01/13/2025 Non-covered Recipient Entity
GI Alliance Department Of Clinical Research And Education
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222306972
Principal investigator 1 Genentech, Inc. $1,256.00 01/13/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLCD B A GI ALLIANCE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663543
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 01/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223273705
Principal investigator 1 Genentech, Inc. $4,940.00 01/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663197
Principal investigator 1 Genentech, Inc. $16,500.00 01/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663238
Principal investigator 1 PFIZER INC. $284.00 01/06/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228724528
Principal investigator 1 PFIZER INC. $122.00 01/06/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775741
Principal investigator 1 PFIZER INC. $300.00 01/06/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228776403
Principal investigator 1 ABBVIE INC. $2,904.00 01/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202435276

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $30,868.96 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $30,868.96 1
PY2022 Amount invested $377.04 1
PY2022 Value of interest $1,938.92 1
PY2021 Amount invested $1,247.84 1
PY2021 Value of interest $1,560.22 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $30,868.96 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124820136
PY2023 GastroGPO, LLC $0.00 $30,868.96 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730559
PY2022 GastroGPO, LLC $377.04 $1,938.92 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955001049
PY2021 GastroGPO, LLC $1,247.84 $1,560.22 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854914679